Patented platforms. Deep bioprocess expertise.
SysGene Biologics:
Process Development.
Built for Production
SysGene Biologics was founded to make essential biologics more accessible and affordable.
We apply bioprocess expertise to develop scalable bacterial and mammalian production processes.
Our expression platforms and bioprocess products help manufacturers improve efficiency and reduce costs while maintaining product quality.
From molecule to manufacture
-
Molecule assessmentStructure, function and quality requirements
-
Platform selectionBacterial secretion or mammalian expression
-
Development & analyticsUpstream, downstream, characterization
-
Scale-up & transfer5 L mammalian; 30–1,000 L microbial; 5,000 L planned
Molecule first
The molecule determines the route, not a one-size-fits-all process.
Every program begins with the molecule’s structure, function and quality requirements, ensuring that the most appropriate platform and development strategy are selected.
Two platform routes
Platform selection follows the molecule
Bacterial secretion
Patented Bacterial Secretion Platform
Designed to produce suitable recombinant proteins and peptides directly into the culture medium. For compatible molecules, extracellular secretion can simplify recovery by reducing reliance on cell lysis, inclusion-body isolation, solubilization and refolding.
Mammalian expression
Patented Mammalian Expression Platform
A CHO-based platform for complex and glycosylated biologics that require mammalian folding, assembly and post-translational processing.
Capabilities
From sequence to a documented, transferable process
Expression, upstream development, recovery, purification, analytical characterization, scale-up and technology transfer, planned around defined program goals.
Feasibility & Expression Strategy
Assess molecule fit, define the target quality profile and select the platform route.
We assess molecular structure, biological function and post-translational processing requirements to evaluate production feasibility and define the target quality profile. Selection of microbial (E. coli/Pichia) or mammalian (CHO/HEK) expression systems considers protein folding, secretion, purification requirements and the intended manufacturing scale.
Manufacture
Analytical and method development, with 5 L mammalian and 30–1,000 L microbial capacity; 5,000 L planned.
We connect non-GMP microbial and mammalian development with GMP microbial manufacture at 30, 100 and 1,000 L. Fermentation and downstream purification are supported by molecule-specific testing for identity, purity, biological activity and process-related impurities, alongside defined product specifications, operating procedures and batch documentation.
Portfolio
Recombinant proteins and bioprocess products
30+ products
Quality & Company
Quality built into development and supply
Development and characterization are aligned with ICH guidelines, and every product is manufactured to the requirements of its stated grade, research grade, multi-compendial or GMP.
Discuss your molecule or product requirement
Tell us what you are developing or sourcing and we will route your enquiry to the right technical and business team.